USPTO serial 85085203
LEADERSHIP IN NANOPHARMACEUTICALS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- EVANKO, PATRICIA MALESARDI
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with LEADERSHIP IN NANOPHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
David Ehrlich
DAVID EHRLICH FROSS ZELNICK LEHRMAN & ZISSU, P.C.866 UNITED NATIONS PLZNEW YORK, NY 10017-1822UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | diagnostic and prognostic preparations for clinical or medical laboratory use; diagnostic and prognostic reagents for identifying a disease or disorder and/or the progression of a disease or disorder | ACTIVE | — |
| 005 | Pharmaceutical preparations for use in the diagnosis and prognosis of oncological diseases or disorders; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of pre-cancerous diseases or disorders; pharmaceutical preparations for use in the diagnosis and prognosis of malignant cancers or neoplasms; pharmaceutical preparations for use in the diagnosis, prognosis and treatment of benign cancers or neoplasms; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of inflammation and inflammatory diseases or disorders; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of cardiovascular diseases or disorders; pharmaceutical preparations for use in modulating angiogenesis; pharmaceutical preparations, namely, drug delivery systems that contain compounds which facilitate the delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, drug delivery systems that contain nanometer scale or nanometer size compounds which facilitate the delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, drug delivery systems that contain polymer and/or lipid based compounds for controlled release of a wide range of pharmaceuticals; pharmaceutical preparations for use in the diagnosis and prognosis of oncological diseases or disorders comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis, prognosis and treatment of pre-cancerous diseases or disorders comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis, prognosis and treatment of benign cancers or neoplasms comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis and prognosis of malignant cancers or neoplasms comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of inflammation and inflammatory diseases or disorders comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of cardiovascular diseases or disorders comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Cerulean Pharma Inc.
- Other trademarks owned by Cerulean Pharma Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Similar marks named LEADERSHIP IN NANOPHARMACEUTICALS
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 17, 2014 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 17, 2014 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 9, 2013 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Aug 8, 2013 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 2, 2013 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 9, 2013 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jul 9, 2013 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 30, 2013 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Jan 29, 2013 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jan 10, 2013 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jan 10, 2013 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 5, 2012 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Sep 5, 2012 | NOAC | CORRECTED NOA MAILED | — |
| Sep 4, 2012 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 4, 2012 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Jul 24, 2012 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jul 24, 2012 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Jul 24, 2012 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Jul 24, 2012 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 7, 2012 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Mar 6, 2012 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 2, 2012 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Feb 8, 2012 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 8, 2012 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 28, 2011 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Jul 26, 2011 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 26, 2011 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 26, 2011 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 8, 2011 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 14, 2010 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 24, 2010 | NPUB | NOTICE OF PUBLICATION | — |
| Nov 10, 2010 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 10, 2010 | ALIE | ASSIGNED TO LIE | — |
| Oct 29, 2010 | CNEA | EXAMINER'S AMENDMENT MAILED | — |
| Oct 28, 2010 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 28, 2010 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 28, 2010 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 28, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 21, 2010 | MPMK | NOTICE OF PSEUDO MARK MAILED | — |
| Jul 20, 2010 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 19, 2010 | NWAP | NEW APPLICATION ENTERED | — |